Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Company Overview - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing biologic therapeutics aimed at restoring immune homeostasis [3] - The company targets potent regulators of the innate and adaptive immune systems to address autoimmune and inflammatory diseases [3] Upcoming Event - Management will participate in a virtual company presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. E.T. [1] - A webcast of the presentation will be available on the company's website, with archived replays accessible for 90 days post-event [2] Product Pipeline - Q32 Bio's lead program, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody currently in a Phase 2 program, aimed at re-regulating adaptive immune function for autoimmune disease treatment [4] - The company also has a program for innate immunity, ADX-097, which is being evaluated in a Phase 2 program and focuses on tissue-targeted regulation of the complement system, differentiating it from current complement therapeutics [4]